Fulcrum Therapeutics Q1 2026 Earnings Narrowing Losses as Pipeline Advances APH Q1 2026 Earnings EPS Smashes Estimates Amid Strong Demand Shares Surge LUXE Q1 2026 Earnings EPS Misses Estimates by 2253 as Stock Edges Lower Recursion Pharmaceuticals RXRX Q1 2026 Earnings Narrower Loss Surprises Market but Stock Dips on PreRevenue Status WLDN Q1 2026 Earnings Strong EPS Beat Drives Positive Market Response ITRI Q1 2026 Earnings Strong EPS Beat Driven by Operational Efficiency and Margin Expansion